drugset / Trial / NCT02812524
Ipilimumab for Head and Neck Cancer Patients
Phase 1
Active not recruiting
18 enrolled
Providence Health & Services
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is for patients with squamous cell carcinoma of the head and neck (SCCHN). This study will test the feasibility of the administration of intratumoral injections of ipilimumab prior to surgical resection, and the immune system response to treatment.
Timeline
- Start
- 2016-11-18
- Primary completion
- 2019-09-21
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 3 mg | Other |